Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809507 | 0.88 | SMN1; SMN2 (0.73) | GAALMNAMAPK1NPC1HPGD | |
| SCHEMBL321631 | 0.85 | HIF1A (0.65) | GAALMNAMAPK1NPC1SMN1; SMN2 | |
| SCHEMBL321291 | 0.83 | ALDH1A1 (0.63) | GAALMNAMAPK1NPC1HPGD | |
| SCHEMBL13948 | 0.83 | MAPT (0.66) | GAALMNAMAPK1NPC1SMN1; SMN2 | |
| SCHEMBL6806801 | 0.81 | MAPT (0.62) | LMNAMAPK1NPC1HPGDSMN1; SMN2 | |
| SCHEMBL6808723 | 0.80 | SMN1; SMN2 (0.60) | MAPK1NPC1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL6809002 | 0.79 | F10 (0.60) | NPC1HPGDSMN1; SMN2RAB9AMAPT | |
| SCHEMBL7477127 | 0.78 | KMT2A (0.64) | GAALMNAMAPK1NPC1SMN1; SMN2 | |
| SCHEMBL18328476 | 0.78 | GAA (0.61) | GAALMNAMAPK1NPC1HPGD | |
| SCHEMBL14096034 | 0.77 | ALDH1A1 (0.65) | GAALMNAMAPK1NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | GAA 4543/4885LMNA 436/4885MAPK1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.